Literature DB >> 7521577

Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

J W Miller1, A P Adamis, D T Shima, P A D'Amore, R S Moulton, M S O'Reilly, J Folkman, H F Dvorak, L F Brown, B Berse.   

Abstract

Ischemia often precedes neovascularization. In ocular neovascularization, such as occurs in diabetic retinopathy, a diffusible angiogenic factor has been postulated to be produced by ischemic retina and to lead to neovascularization of the retina, optic nerve, or iris. However, no angiogenic factor has been conclusively identified that satisfies this hypothesis. Vascular endothelial growth factor/vascular permeability factor, hereafter referred to as VEGF, is a likely candidate for an ocular angiogenic factor because it is a secreted mitogen, specific for endothelial cells, and is upregulated by hypoxia. We investigated the association of VEGF with the development of experimental iris neovascularization in the cynomolgus monkey. Following the production of retinal ischemia by laser occlusion of all branch retinal veins, VEGF was increased in the aqueous fluid, and the aqueous VEGF levels changed synchronously and proportionally with the severity of iris neovascularization. Northern analysis and in situ hybridization revealed that VEGF messenger RNA is upregulated in the ischemic retina. These observations support the hypothesis that ocular neovascularization is regulated by a diffusible factor and identify VEGF as a likely candidate for a retina-derived vascular permeability and angiogenesis factor in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521577      PMCID: PMC1890317     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Retinal vascularization in health and disease: Proctor Award Lecture of the Association for Research in Ophthalmology.

Authors:  N ASHTON
Journal:  Am J Ophthalmol       Date:  1957-10       Impact factor: 5.258

2.  Regression of experimental iris neovascularization with systemic alpha-interferon.

Authors:  J W Miller; W G Stinson; J Folkman
Journal:  Ophthalmology       Date:  1993-01       Impact factor: 12.079

3.  Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products.

Authors:  H F Dvorak; N S Orenstein; A C Carvalho; W H Churchill; A M Dvorak; S J Galli; J Feder; A M Bitzer; J Rypysc; P Giovinco
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

4.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

5.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

6.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

Authors:  L F Brown; B Berse; R W Jackman; K Tognazzi; E J Manseau; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

7.  Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies.

Authors:  T M Sioussat; H F Dvorak; T A Brock; D R Senger
Journal:  Arch Biochem Biophys       Date:  1993-02-15       Impact factor: 4.013

Review 8.  Vascular permeability factor (VPF, VEGF) in tumor biology.

Authors:  D R Senger; L Van de Water; L F Brown; J A Nagy; K T Yeo; T K Yeo; B Berse; R W Jackman; A M Dvorak; H F Dvorak
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

9.  Angiogenic activity from bovine retina: partial purification and characterization.

Authors:  P A D'Amore; B M Glaser; S K Brunson; A H Fenselau
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

10.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Authors:  K T Yeo; H H Wang; J A Nagy; T M Sioussat; S R Ledbetter; A J Hoogewerf; Y Zhou; E M Masse; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

View more
  173 in total

1.  A fragment of human TrpRS as a potent antagonist of ocular angiogenesis.

Authors:  Atsushi Otani; Bonnie M Slike; Michael I Dorrell; John Hood; Karen Kinder; Karla L Ewalt; David Cheresh; Paul Schimmel; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

2.  Is diabetic retinopathy an inflammatory disease?

Authors:  A P Adamis
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

3.  Photodynamic therapy for choroidal neovascularization. The Jules Gonin Lecture, Montreux, Switzerland, 1 September 2002.

Authors:  Joan W Miller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-11       Impact factor: 3.117

Review 4.  Vascular potential of human pluripotent stem cells.

Authors:  Ionela Iacobas; Archana Vats; Karen K Hirschi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-07       Impact factor: 8.311

Review 5.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

Review 6.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

Review 7.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

8.  Plasma endothelin-1 concentrations in patients with retinal vein occlusions.

Authors:  A Iannaccone; C Letizia; S Pazzaglia; E M Vingolo; G Clemente; M R Pannarale
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

9.  VEGF localisation in diabetic retinopathy.

Authors:  M Boulton; D Foreman; G Williams; D McLeod
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

10.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

Authors:  L P Aiello; E A Pierce; E D Foley; H Takagi; H Chen; L Riddle; N Ferrara; G L King; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.